Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Halozyme Therapeutics |
---|---|
Information provided by: | Halozyme Therapeutics |
ClinicalTrials.gov Identifier: | NCT00705536 |
The purpose of the study was to compare the pharmacokinetics and pharmacodynamics of Humalog or Humulin R insulin when administered as a single 20-U subcutaneous (SC) injection with or without coadministration of rHuPH20.
The study hypothesizes that the time required to reach maximum insulin concentration (Tmax) when insulin is administered with rHuPH20 will be comparable or shorter than the time required without rHuPH20.
Condition | Intervention | Phase |
---|---|---|
Insulin Diabetes Volunteers |
Drug: Humalog Drug: Humulin R |
Phase I |
Study Type: | Interventional |
Study Design: | Health Services Research, Randomized, Double Blind (Subject, Investigator), Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Phase I, Randomized, Double-Blind Crossover Pharmacokinetic, Pharmacodynamic and Safety Study of Subcutaneously Administered Humalog® (Insulin Lispro Injection; Fast-Acting Insulin) With and Without Recombinant Human Hyaluronidase (rHuPH20) Versus Subcutaneously Administered Humulin R® (Regular Insulin Injection) With and Without rHuPH20 |
Enrollment: | 26 |
Study Start Date: | January 2008 |
Study Completion Date: | March 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Stage 1: Active Comparator
Subjects randomized to Humalog with or without rHuPH20
|
Drug: Humalog
20 U of Humalog with or without 300 U of rHupH20
|
Stage 2: Active Comparator
Subjects randomized to Humulin R with or without rHuPH20
|
Drug: Humulin R
20 U of Humulin R with or without 240 U rHuPH20
|
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
DGD Research, Inc. | |
San Antonio, Texas, United States, 78229 |
Principal Investigator: | Mark S. Kipnes, MD | Diabetes and Glandular Disease Research Associates Inc. |
Responsible Party: | Halozyme Therapeutics ( Richard Yocum, M.D., Vice President of Clinical Dev and Med Affairs ) |
Study ID Numbers: | HZ2-07-04 |
Study First Received: | June 24, 2008 |
Last Updated: | June 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00705536 |
Health Authority: | United States: Food and Drug Administration |
rHuPH20 Hyaluronidase Insulin |
Diabetes Mellitus Insulin LISPRO Insulin |
Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |